Table 2.

North American Olanzapine Trial: BPRS Total Score Mean Change^a From Baseline by Treatment and Week and Time Course of Estimated Treatment Effects

Week	Placebo		Haloperidol		Olanzapine 5 mg		Olanzapine 10 mg		Olanzapine 15 mg
Changes from baseline
	Mean	SE	Mean	SE	Mean	SE	Mean	SE	Mean	SE
Baseline	58.7	1.4	60.1	1.3	58.9	1.5	61.3	1.3	60.6	1.3
1	−3.2	1.6	−11.6	1.6	−5.9	1.6	−7.6	1.6	−10.9	1.6
2	−3.8	1.7	−14.8	1.6	−8.2	1.7	−9.7	1.6	−13.3	1.7
3	−4.7	1.9	−14.8	1.8	−9.1	1.9	−10.7	1.8	−14.5	1.8
4	−5.0	2.0	−15.0	1.8	−10.0	2.0	−12.5	1.9	−16.2	1.9
5	−6.7	2.2	−15.2	2.0	−9.1	2.1	−14.2	2.1	−16.8	2.0
6	−8.6	2.2	−15.9	2.0	−10.7	2.1	−17.6	2.1	−20.0	1.9
Differences from placebo
			Diff	%max	Diff	%max	Diff	%max	Diff	%max
1			8.4	76.6	2.8	55.5	4.4	49.2	7.7	68.1
2			11.0	100.0	4.5	89.0	5.9	65.3	9.5	84.1
3			10.1	91.8	4.4	88.2	6.0	66.4	9.8	86.4
4			10.0	90.5	5.0	100.0	7.5	83.3	11.2	98.8
5			8.5	77.1	2.4	47.7	7.4	82.7	10.0	88.5
6			7.2	65.8	2.1	42.1	9.0	100.0	11.3	100.0

^aEstimated from mixed model for incomplete repeated measures: D_ikt = week_t + treatment_k + week_t × treatment_k + error. Observed means and SEs are presented for baseline BPRS total score